Tandem Diabetes Care Inc. has announced a new partnership with Abbott to enhance diabetes management technology. The collaboration integrates Tandem's t:slim X2™ insulin pump, equipped with Control-IQ+ automated insulin delivery technology, with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring sensor. This integration aims to offer personalized solutions for people living with diabetes by allowing the insulin pump to receive automatic glucose readings every minute from the sensor. The partnership is set to expand the availability of this integrated system in the United States starting the second half of 2025, with plans to extend access to international markets later this year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。